News

Under the terms of the agreement, SalvaRx will invest US$1,000,000 for an initial holding of approximately 30% (including new shares issued on the conversion of a US$90,000 convertible

In May 2014, both firms signed a worldwide research collaboration and license agreement to discover, develop and commercialize novel therapies against multiple immuno-oncology targets using CytomX’s Probody platform. The

Circassia has agreed to pay AstraZeneca $50m worth of its ordinary shares under the deal, which is expected to complete in the second quarter of this year. Circassia also

HFrEF is also known as systolic heart failure (HF). Entresto is indicated to reduce the risk of cardiovascular (CV) death and hospitalization for HF in patients with chronic

The trial demonstrated that Repatha has maximum reduced low-density lipoprotein cholesterol (LDL-C) levels, helping to decrease the risk of major cardiovascular events such as heart attacks, strokes and

The European Commission (EC) has approved the label extension application, granting three new indications for Cinryze, which expands its coverage to treat children with hereditary angioedema (HAE). Cinryze

Cell Medica will use the investment capital to continue to progress its three proprietary technology platforms for cell-based immunotherapy products. The Company’s lead oncology product, baltaleucel-T (CMD-003), is

Emflaza is the first treatment approved in the US for all Duchenne muscular dystrophy (DMD) patients five years and older, regardless of their genetic mutation. DMD is a rare

The decision means that eligible adults with severe AD can access dupilumab before the drug is granted marketing authorisation in the UK. Allergy UK CEO Carla Jones said: